CD274 and breast carcinoma: Many tumors neither display PD-L1 (Programmed Cell Death Ligand 1) expression nor are BRCA (Breast Cancer)-1/2 mutations present, rendering these patients ineligible for checkpoint or PARP (Poly (ADP-ribose)-Polymerase) inhibitors in the metastatic setting [2].